Novel Prognostic Markers in Renal Cancer
Recruitment status was Recruiting
The purpose of this project is to analyze tumour tissue from a group of subjects with renal cell carcinoma, who have been treated at the Royal Marsden Hospital.
Renal Cell Carcinoma
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Novel Prognostic Markers in Renal Cancer: a Protocol for the Analysis of Paraffin Embedded Tumour Samples|
- The profiling of the expression of signal transduction biomarkers, gene expression, gene copy numbers and effect of mutations of the VHL gene in renal cancer and their relationship to clinical outcomes. [ Designated as safety issue: No ]
|Study Start Date:||December 2008|
|Estimated Study Completion Date:||March 2011|
|Estimated Primary Completion Date:||March 2011 (Final data collection date for primary outcome measure)|
Tumour tissue, renal cell carcinoma
> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens.
Renal cancers have different clinical outcomes. The principal research objective is to study tumour tissue from renal cancer patients and try and understand why some cancers progress more rapidly than others. Further, another key aim of this study is to try and understand why some patients respond to treatment and others do not.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01002937
|Contact: Professor Martin Gorefirstname.lastname@example.org|
|Royal Marsden NHS Foundation Trust||Recruiting|
|Sutton, Surrey, United Kingdom, SM2 5PT|
|Principal Investigator:||Professor Martin Gore||Royal Marsden NHS Foundation Trust|